Wyndham Philadelphia Historic District / Philadelphia, PA
Ease the complexity of successful implementation of centralized monitoring in a risk-based monitoring (RBM) approach to optimize data quality & improve clinical efficiency
Central Monitoring – Central Monitoring Summit
Successfully introducing new drugs and therapies in a quicker and more cost-effective manner starts in the most complex phase on of drug development; the clinical phase. The implementation of risk-based monitoring increases the overall quality of data while providing better oversight of patient safety. With the introduction of centralized monitoring in a risk-based monitoring approach, pharmaceutical companies are able to embrace a real-time overview of data and risk detection.The Central Monitoring Summit will arm delegates with the tools they need to optimize existing clinical operation platforms and build quality into the design for a sound central monitoring foundation. Join your colleagues and our expert speaking staff as they provide in-depth insights into shifting your monitoring processes from an excessive concentration of data to risk-driven monitoring that uses central monitoring and technology enablement.
LISA BERDAN, PA, MHS, Executive Director, Global Megatrials, DUKE CLINICAL RESEARCH INSTITUTE
KIMBERLY D. NESSEL, MSN, Director, Clinical Scientist CVM, THE JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON
Discuss Case Studies and Practical Solutions Across Pharma on the Successful Implementation of Centralized Monitoring
Adopt Change Management and Infrastructure Changes Needed in Adoption of Central and Remote Monitoring Practices
Fine-Tune Responsibilities or Job Description of the Central Monitor
Use Predictive Analysis for a Central CRA or Study Manager to Understand the Trends in Clinical Data and to See Critical Development Earlier
Who Should Attend
This conference is designed for Life Sciences representatives with responsibilities in:
Clinical Data/Trial Management
Clinical Research Associates (CRAs)
The conference will benefit monitoring supplier groups, including:
While I’m 10+ years in the industry (18 months in Quality), I learned a lot! Great networking.
Senior Clinical Quality Manager, NOVARTIS
Discussions, presentations, interactions have provided a clear picture of common issues
VP Quality, ALTASCIENCES
I was able to find weaknesses in my process that I will need to review
Director, CQA, TREVENA
Members could share struggles, challenges, and ideas. It was also a good forum to build my network. As the conference went on, people seemed to share more lessons learned, shared learning, and tip/tricks. I liked this. It’s more helpful to share challenges that are followed by solutions.